Bovine Mastitis Market Report Scope & Overview:

The Bovine Mastitis Market size was USD 0.64 Billion in 20255 and is expected to reach USD 1.19 Billion by 2035 and grow at a CAGR of 6.4% over the forecast period of 2026-2035.

Bovine Mastitis Market Size and Forecast:

• Market Size in 2025: USD 0.64 Billion

• Market Size by 2035: USD 1.19 Billion

• CAGR: 6.4% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

Key Bovine Mastitis Market Trends:

• Rising awareness among dairy farmers about the impact of udder health on milk yield and quality drives adoption of mastitis prevention and treatment solutions.

• Increasing use of advanced diagnostic tools, including somatic cell count monitoring and automated sensors, enables early detection and timely intervention, reducing economic losses.

• Strict government regulations on antibiotic usage and residue limits in milk encourage the development and adoption of alternative therapies and preventive measures.

• Growing dairy production and consumption in emerging regions create opportunities for market expansion, with increased demand for vaccines, antibiotics, and hygiene products.

• Integration of herd management software and IoT-based monitoring enhances disease tracking, operational efficiency, and herd productivity.

The U.S. Bovine Mastitis market size was estimated at USD 0.22 billion in 2025 and is projected to reach USD 0.36 billion by 2035, growing at a CAGR of 6.3% during the forecast period of 2026-2035. The market growth is fueled by the large number of mastitis cases in dairy cows, the rising concern for animal health and milk quality, and the rising demand for dairy products in the country. The increasing use of advanced diagnostic equipment, better veterinary treatment options, and preventive measures for dairy herds are fueling the growth of the market. Furthermore, the rising concern among dairy farmers, government support for the health of livestock, and innovations in veterinary drugs are also contributing to the steady growth of the U.S. Bovine Mastitis market.

Bovine Mastitis Market Drivers:

• The demand for milk and dairy products continues to rise due to population growth, changing dietary preferences, and increased urbanization.

Many dairy farmers are beginning to realize that the health of their cows greatly affects both the quantity and quality of milk they produce. Mastitis is a disease causing up to 22% economic losses in dairy herds, involving an inflammation of mammary gland. It cuts down the milk production and results in altered milk composition leading to economic loss from discarded milk, veterinary cost and farm inefficiency (Kahn et al. Farmers are now utilizing preventative strategies to alleviate these effects, including proper milking hygiene, routine udder health monitoring and nutritional strategies. At the herd-level management, technologies for early detection such as monitoring of somatic cell counts (SCC) and automatic health sensors are being incorporated. These preventive actions help to promote lactating herd productivity, enhance milk quality and maximize dairy farm profitability.

Bovine Mastitis Market Restraints:

• The overuse or misuse of antibiotics for the treatment of bovine mastitis has contributed to the development of antibiotic-resistant bacteria.

In an effort to ensure the safety of food and the health of the public, governments and regulatory authorities are laying down much stricter regulations on the use of antibiotics and pharmaceuticals in the dairy sector. The regulations frequently have restrictions on the types, dosages and length of collections of antibiotics, as well as setting maximum residue limits in milk. This makes it difficult for dairy farmers to control a prevalent and financially significant udder infection — mastitis. The limitation of access to traditional antibiotics postpones treatment which could compromise animal welfare as well as milk yield and quality. Inorder not only to keep the herd healthy but also not to hamper productivity farmers are seeking alternatives strategies like preventive/health care, good hygienic practices, vaccination programs and non-antibiotic therapies, to implement and comply with regulations without regulating the economics and operational or production status.

Bovine Mastitis Market Opportunities:

• Continued research and development in diagnostic technologies can lead to the introduction of more rapid, accurate, and cost-effective mastitis detection methods.

The bovine mastitis market offers high potential opportunity over emerging regions, where dairy production and consumption is increasing. The traditional dairy farm practice is now changing in developing countries, which includes better herd management, milking hygiene, and veterinary services; with growing expertise, the need for good mastitis prevention and treatment solutions is increasing. Increasing knowledge about economic losses due to mastitis in reduction of milk yield and quality strengthens the use of antibiotics, vaccines and diagnostic tools. Furthermore, market demand is boosted by government schemes for dairy and availability of animal health infrastructure. As a result, mastitis-related products related to mastitis are a primary market and emerging markets for mastitis-related products make it extreme easy for manufacturers and service providers to make an overall appearance in a particular region and start a current sources there.

Bovine Mastitis Market Segmentation Analysis:

By Product, the Antibiotics Segment Dominates the Bovine Mastitis Market in 2025, and the Other Therapies Segment Exhibits the Fastest Growth in the Bovine Mastitis Market

With the largest revenue share of 59% in 2025, the Antibiotics segment held the dominant share of the bovine mastitis market. The treatment and prevention of mastitis infections through the administration of antibiotics directly impacts milk yield and quality, contributing to the dominance of this category on antibiotic use in dairy cattle. With the focus on herd health and the ever-increasing demand for effective antibiotic treatments. Be it novel formulations or antibiotic with an assurance of residue free milk, continuous product development complements the allocation of the market space, which continues to be guaranteed not only by the robustness of the product but also by the capability of antibiotics as cornerstone therapy in mastitis management. The Other segment is anticipated to have the highest CAGR during the forecast period. The upsurge is due to increasing uptake of non-antibiotic type therapies (herbal, probiotic, and vaccine). With increasing regulatory restrictions on the use of antibiotics, farmers are looking for alternatives that maintain udder health and, at the same time, do not affect milk safety. New choice helps in clever care and product development to speed up the adoption of mastitis control some other options while also accelerating the growth in the marketplace of usually unproblematic and residue-free dairy farming.

By Route of Administration, Intramammary Administration Leads the Bovine Mastitis Market in 2025, Systemic Administration Shows the Highest CAGR in the Bovine Mastitis Market

In 2025, the highest revenue share, at 53%, was owed to the Intramammary segment within the bovine mastitis market. It is because it applies directly to the udder and offers fast treatment of the infections. Due to their impact on reducing the duration of infection and improving milk quality, dairy farmers are increasing their use of intramammary therapies. Continuous product development of intramammary formulations with better efficacy, lower withdrawal periods and simpler administration also drives market, cementing its position as a market leader in mastitis treatment. Systemic is the fastest-growing segment over the forecast period with a CAGR of 13.71% during 2026–2035. Growth is due to strong demand for systemic therapies for severe or multi-quinolone infections. The systemic antibiotics provide wide therapeutic coverage for the animals, enabling quick recovery and limiting production losses. Innovations in drug formulations ,long-acting injectables and improved bioavailability, facilitate streamlined treatment regimens. As a result of this, systemic administration is coming into vogue for dairy farmers, supporting the market of integrated mastitis management.

By Application, On-site Treatment Commands Largest Revenue Share in Bovine Mastitis Market, Veterinary Clinics and Hospitals Segment Growing Fastest in Bovine Mastitis Market

Based on the treatment, the bovine mastitis market is segmented into on-site treatment and off-site treatment and was dominated by the On-site Treatment segment which accounted for 54% revenue share, respectively, in 2025. This is due to the convenience, and immediacy of treating cows directly on the farm, minimizing spread of infection and milk loss. Dairy farmers favour interventions that have been shown to be effective under field conditions and can provide a quantitative measurement of herd health status. The development of rapid acting products that are easy to administer have driven mastitis management from the vet clinic into the dairy barn, and the market is supported by the continuous improvements in the ease of use of the products enabling improved on-site mastitis management from which both the veterinary industry and dairy sector can achieve their goals of improved efficiency and higher productivity. During the forecast period, the Veterinary Clinics and Hospitals segment recorded the highest CAGR.

Bovine Mastitis Market Regional Analysis:

North America Dominates the Bovine Mastitis Market in 2025

North America holds an estimated 38% market share in 2025, driven by high adoption of advanced dairy farming practices, precision livestock monitoring, and veterinary services. This causes farmers to invest heavily in mastitis prevention and treatment solutions, improving milk quality and herd health while boosting demand for antibiotics and alternative therapies.

• United States Leads North America’s Bovine Mastitis Market

The U.S. dominates the North American market due to its large-scale, technologically advanced dairy farms and strong veterinary infrastructure. High milk production volumes and stringent quality standards increase the need for effective mastitis management solutions. Government initiatives supporting dairy health programs and research in veterinary pharmaceuticals further drive adoption. Additionally, U.S. dairy farmers increasingly use intramammary treatments, systemic antibiotics, and on-site interventions, creating steady demand for both traditional and innovative mastitis products, reinforcing the country’s leadership in the regional market.

Asia Pacific is the Fastest-Growing Region in Bovine Mastitis Market in 2025

The region is expected to grow at a CAGR of 8.9% from 2026–2035, driven by modernization of dairy farms, rising milk consumption, and increased awareness of herd health. This causes adoption of advanced mastitis management solutions, including antibiotics, alternative therapies, and veterinary services.

• India Leads Asia Pacific’s Bovine Mastitis Market

India dominates the Asia Pacific market due to its position as one of the largest milk producers globally. Rapid growth in commercial dairy farming, government initiatives promoting livestock health, and adoption of modern treatment practices accelerate market expansion. Increasing awareness among farmers about mastitis impact on milk yield and quality drives demand for antibiotics, herbal remedies, and intramammary therapies. Investment in veterinary clinics and on-site treatment options further strengthens the market, positioning India as the leading contributor to the region’s bovine mastitis growth.

Europe Bovine Mastitis Market Insights, 2025

Europe shows steady growth in bovine mastitis solutions, supported by high-quality dairy production and strict milk safety regulations. The U.K.’s focus on herd health programs and antimicrobial stewardship improves dairy productivity, causing increased adoption of mastitis management solutions.

• Germany Leads Europe’s Bovine Mastitis Market

The extensive dairy farm infrastructure, high milk output, and strict quality guidelines have all led to Germany dominating Europe’s market. In Germany, a strong emphasis on preventive medicine means widespread use of both intramammary therapies and systemic antibiotics as well as new veterinary pharmaceuticals to replace them. Veterinary research, monitoring for antimicrobials and clearing residues from milk are further supported by government which facilitates adoption. With a continuous product development and accessibility of professional veterinary services, mastitis is easily managed allowing for Germany to remain as the European leader in the bovine mastitis market.

Middle East & Africa and Latin America Bovine Mastitis Market Insights, 2025

Moderate growth is expected for the bovine mastitis market in all these regions attributed to culture of high dairy consumption, modernization of dairy farms and increased awareness of herd health. Brazil and Mexico are investing in preventive care and veterinary services, while the UAE and South Africa are interested in herd management technologies and treatments at the site. The combination of a growing dairy production and the demand for safe quality milk is fuelling the use of antibiotics, intramammary therapies, and alternative mastitis solutions across the world. Steady growth in the regions is supported by international collaborations and product innovations.

Competitive Landscape for Bovine Mastitis Market:

Zoetis Inc.

Zoetis Inc. is a major global animal health firm focused on serving customers and their businesses throughout the animal health continuum. Zoetis is headquartered in the U.S. and has expertise in vaccines, antibiotics, and therapeutic approaches, such as bovine mastitis treatment. The firm has been engaged in the development, manufacture, and marketing of products to enhance herd health, milk quality, and disease protection for many years. Zoetis, a major animal health firm, is a global business that puts veterinary expertise, support, and comprehensive treatment programs in the hands of farmers. The bovine mastitis market is API, which is very important and provides an opportunity to lower infection rates and make sustainable dairy production.

• In 2024, Zoetis expanded its mastitis portfolio with advanced intramammary formulations and residue-safe antibiotics, targeting higher efficacy and faster recovery in dairy herds.

Merck Animal Health (MSD)

MSD Animal Health (Merck in Canada) is a world leader in veterinary pharmaceuticals and vaccines providing total solutions for bovine mastitis prevention and treatment. The firm specializes in antibiotic, immunotherapy and diagnostic tools to support herd health and milk superlative. Merck teams up with dairy farmers and vet professionals to have standardized protocols of treatment, leading to better outcomes. It is an important player in the bovine mastitis market, encouraging innovations and a sustainable management practice so that infections lead to reduced economic losses.

• In 2024, Merck launched new mastitis vaccines and intramammary therapies designed to lower infection recurrence and enhance milk safety, supporting farmer adoption of integrated herd health programs.

Boehringer Ingelheim

Boehringer Ingelheim is a multinational Germany-based company focused on animal health solutions, including mastitis control for dairy cattle. They offer antibiotics, vaccines, and preventive care tools to increase herd immunity and improve milk quality. Boehringer Ingelheim collaborates with veterinarians and farmers to refine treatment protocols and farmers to help ensure sustainable practices in dairy farming. It is indispensable in the bovine mastitis market by addressing the growing need in the market with innovative and reliable products that reduce the prevalence of infection with operational efficiency.

• In 2024, Boehringer Ingelheim introduced advanced intramammary treatments with faster action and reduced withdrawal periods, improving compliance and productivity in commercial dairy operations.

Elanco Animal Health

Elanco Animal Health is a U.S. global animal health company offering a broad portfolio of vaccines, therapeutics, and preventive solutions focused on helping animals live their best lives, including bovine mastitis. Through a focus on innovation, herd health management, and product development, the company works to support dairy farmers all over the world. Elanco's role in the mastitis space is holistic, it solves operational capabilities with integrated solutions to help sustain milk quality, reduce disease occurrences, and in turn enhance dairy economics.

• In 2024, Elanco rolled out novel antibiotic and non-antibiotic therapies, combined with herd monitoring tools, enabling effective mastitis management and promoting sustainable, residue-free milk production.

Bovine Mastitis Market Key Players:

• Zoetis Inc.

• Merck Animal Health (MSD)

• Boehringer Ingelheim

• Elanco Animal Health

• Ceva Santé Animale

• Vetoquinol S.A.

• Virbac

• Phibro Animal Health Corporation

• Hester Biosciences

• Indian Immunologicals Ltd.

• Biovac

• Vaxxinova

• Biogénesis Bago

• Laboratorios Hipra S.A.

• IDT Biologika GmbH

• Huvepharma

• Norbrook Laboratories

• Fatro S.p.A.

• Lohmann Animal Health

• Dairy Tech